Subscribe: Marketwire - Financial Agreements
http://www.marketwire.com/rss/fnc.xml
Preview: Marketwire - Financial Agreements

Marketwired - Financial Agreements



Marketwired - Financial Agreements



Last Build Date: Fri, 16 Feb 2018 18:07:32 EST

Copyright: Copyright: (C) Marketwired
 



Pieris Pharmaceuticals Announces Closing of Public Offering and Exercise of Underwriters' Option to Purchase Additional Shares

Fri, 16 Feb 2018 17:36:17 EST

BOSTON, MA--(Marketwired - February 16, 2018) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for cancer, respiratory and other diseases, announced today the closing of its previously announced underwritten public offering and the exercise in full of the underwriters' option to purchase additional shares. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Pieris, are $50.6 million. 6,325,000 shares of common stock at a public offering price of $8.00 per share were issued and sold in the offering, which includes 825,000 shares issued upon the exercise of the underwriters' option to purchase additional shares, less the underwriting discounts and commissions.




Motus GI Announces Closing of Initial Public Offering

Fri, 16 Feb 2018 16:05:00 EST

FORT LAUDERDALE, FL--(Marketwired - February 16, 2018) - Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus" or the "Company"), a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today the closing of its initial public offering of 3,500,000 shares of its common stock at a public offering price of $5.00 per share, with gross proceeds of $17.5 million. Additionally, Motus has granted the underwriters a 30-day option to purchase an additional 525,000 shares of its common stock at the initial public offering price, less the underwriting discount and commissions, to cover over-allotments.




Moleculin Announces Pricing of $9 Million Registered Direct Offering

Fri, 16 Feb 2018 08:28:56 EST

HOUSTON, TX--(Marketwired - February 16, 2018) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that it has entered into a definitive agreement with institutional investors for a registered direct offering of securities with gross proceeds of approximately $9 million. The closing of the offering is expected to take place on or about February 21, 2018, subject to the satisfaction of customary closing conditions.




Alopex Gold Inc. Announces the Filing of a Preliminary Short Form Prospectus

Thu, 15 Feb 2018 11:03:07 EST

TORONTO, ONTARIO--(Marketwired - Feb. 15, 2018) -